Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QRFPR | Q96P65 | 4/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.38 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | NPY4R | P50391 | 9/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.37 |
| ▸ | NPY1R | P25929 | 7/20 | 0.37 |
| ▸ | NPY2R | P49146 | 5/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29630453 | 0.99 | PTGS1 (0.39) | QRFPRPTGS1GSTK1GLO1NPY4R | |
| SCHEMBL30997463 | 0.98 | QRFPR (0.41) | QRFPRPTGS1GSTK1GLO1NPY4R | |
| SCHEMBL30373025 | 0.96 | QRFPR (0.41) | QRFPRPTGS1GSTK1GLO1NPY4R | |
| SCHEMBL30372279 | 0.96 | QRFPR (0.41) | QRFPRPTGS1GSTK1GLO1NPY4R | |
| SCHEMBL29590376 | 0.96 | QRFPR (0.42) | QRFPRPTGS1GSTK1GLO1NPY4R | |
| SCHEMBL29630426 | 0.96 | QRFPR (0.42) | QRFPRPTGS1GSTK1GLO1NPY4R | |
| SCHEMBL29354257 | 0.95 | PTGS1 (0.41) | QRFPRPTGS1GSTK1GLO1NPY4R | |
| SCHEMBL31589116 | 0.93 | NMT1 (0.41) | QRFPRNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL21961850 | 0.93 | ITGB3 (0.40) | QRFPRPTGS1GSTK1GLO1NPY4R | |
| SCHEMBL19426331 | 0.93 | ITGB3 (0.40) | QRFPRPTGS1GSTK1GLO1NPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | QRFPR 859/4885PTGS1 3202/4885GSTK1 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.